Reports on the anti-CD38 antibody isatuximab showed that isatuximab-based therapies (isatuximab plus pomalidomide and dexamethasone, or isatuximab plus carfilzomib and dexamethasone) improved PFS for patients with relapsed or refractory MM and gain/amp(1q21) versus standard-of-care therapy alone [37, 38]. Here, CD38 is linked to Miyoshi myopathy.